Welcome to our dedicated page for PTNTD SEC filings (Ticker: PTNTD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTNTD SEC filings page aggregates regulatory documents for Palatin Technologies, Inc. that are associated with this symbol and related trading symbols referenced in the company’s disclosures. Palatin Technologies, Inc. files with the U.S. Securities and Exchange Commission as a Delaware corporation, as noted in its Form S-1/A registration statement, which also identifies a primary Standard Industrial Classification code of 2834.
On this page, users can review current reports on Form 8-K in which the company describes material events such as notices from NYSE American regarding listing suitability, the suspension of trading on that exchange, subsequent trading on OTC markets under the symbol "PTNT," and the company’s efforts to regain compliance with continued listing standards. These 8-K filings also cover underwriting agreements with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd., detailing public offerings of common stock, pre-funded warrants, Series J and Series K warrants, and underwriter warrants.
The Form S-1/A registration statement available through this page outlines the structure of a firm commitment public offering, including the number of shares of common stock and warrants being registered, the assumed combined public offering price range, and the terms of the Series J and Series K common stock purchase warrants and pre-funded warrants. It also discusses conditions related to the re-listing of the company’s common stock on the NYSE American exchange.
In addition, 8-K filings describe a collaboration agreement with Boehringer Ingelheim International GmbH, including upfront and milestone payments and the potential for additional success-based payments and royalties. Stock Titan’s interface can pair these filings with AI-powered summaries that explain the key terms of offerings, warrant structures, listing status changes, and collaboration arrangements, helping readers interpret lengthy documents such as 8-Ks and S-1/A filings more efficiently while they research PTNTD-related information.
Palatin Technologies, Inc. reported that it achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a €5.5 million ($6.5 million) payment to Palatin. This payment adds to an earlier upfront payment of €2.0 million ($2.3 million) and is part of up to €18.0 million ($21.2 million) in near-term research milestones available under the agreement.
Beyond these near-term milestones, Palatin is eligible for as much as €260 million ($307 million) in success-based development, regulatory, and commercial milestone payments, plus tiered royalties on net sales from any products that emerge from the collaboration. Separately, the company notes that its common stock was found no longer suitable for listing on NYSE American due to a low selling price, was suspended from trading on that exchange on May 7, 2025, and now trades on the OTCQB Market under the symbol “PTNT”.